The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker
Open Access
- 26 March 2022
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 10 (2) , e00937
Abstract
Atrial fibrillation (AF) is a major risk factor for stroke. We aim to characterize AF patients and the effects of apixaban therapy in terms of clot microstructure using gel point analysis, a novel biomarker. Seventy‐eight patients were included in the study, 50 Stroke with AF (AF‐S), and 28 AF without stroke (AF). Pre‐ and post‐anticoagulation samples were collected: gel point (GP) analysis was performed to obtain (i) TGP (the time taken to reach the GP or the clot formation time) and (ii) df, the fractal dimension of the clot, a quantification of clot fibrin microstructure at the GP. At baseline, the AF‐S group had a df = 1.70 (±0.05) and TGP = 306 (±73 s). The AF group had a df = 1.70 ± 0.05 and TGP = 346 ± 78 s, showing a significantly shortened TGP in the stroke group (p = .008). For both groups, apixaban significantly prolonged TGP, p = .005, but resulted in no change in df. Apixaban prolonged clotting time while having no significant impact on the blood’s ability to form stable clots (no change in df). This indicates that apixaban provides protection from the formation of thrombi by reducing clotting kinetics.Keywords
Funding Information
- Bristol-Myers Squibb (CV185‐621)
This publication has 32 references indexed in Scilit:
- A new biomarker quantifies differences in clot microstructure in patients with venous thromboembolismBritish Journal of Haematology, 2014
- Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidenceAnnals of Medicine, 2014
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Validation of the CHADS2 clinical prediction rule to predict ischaemic strokeThrombosis and Haemostasis, 2011
- Pathophysiological Mechanisms of Atrial Fibrillation: A Translational AppraisalPhysiological Reviews, 2011
- Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasmaJournal of Enzyme Inhibition and Medicinal Chemistry, 2010
- Gel point and fractal microstructure of incipient blood clots are significant new markers of hemostasis for healthy and anticoagulated bloodBlood, 2010
- Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor XaJournal of Medicinal Chemistry, 2007
- Additive Role of Plasma von Willebrand Factor Levels to Clinical Factors for Risk Stratification of Patients With Atrial FibrillationStroke, 2006
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991